Founded out of Université catholique de Louvain and Wageningen University research, A-Mansia Biotech hopes to commercialise nutritional supplements for patients at heightened cardio-metabolic risk.
A-Mansia Biotech, a Belgium-based microbiome therapeutics spinout of Université catholique de Louvain (UCL) and Wageningen University, increased its series A round to €18m ($20.3m) today with an extension from venture fund Innovation Industries.
The contribution follows an initial $15.7m series A close in April 2018 led by VC firm Seventure Partners that featured Fonds Vives II, a university venture fund of UCL.
State-owned regional development vehicle Société Régionale d’Investissement de Wallonie also took part in the first…